Fomivirsen sodium - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for fomivirsen sodium and what is the scope of freedom to operate?

Fomivirsen sodium is the generic ingredient in one branded drug marketed by Novartis and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for fomivirsen sodium

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	4
Patent Applications:	1,015
DailyMed Link:	fomivirsen sodium at DailyMed

Recent Clinical Trials for fomivirsen sodium

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ionis Pharmaceuticals, Inc.	Phase 2
Ionis Pharmaceuticals, Inc.	N/A

See all fomivirsen sodium clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for fomivirsen sodium

S01AD	Antivirals
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for fomivirsen sodium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	VITRAVENE PRESERVATIVE FREE	fomivirsen sodium	INJECTABLE;INJECTION	020961-001	Aug 26, 1998		DISCN	No	No

Expired US Patents for fomivirsen sodium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	VITRAVENE PRESERVATIVE FREE	fomivirsen sodium	INJECTABLE;INJECTION	020961-001	Aug 26, 1998
Novartis	VITRAVENE PRESERVATIVE FREE	fomivirsen sodium	INJECTABLE;INJECTION	020961-001	Aug 26, 1998
Novartis	VITRAVENE PRESERVATIVE FREE	fomivirsen sodium	INJECTABLE;INJECTION	020961-001	Aug 26, 1998
Novartis	VITRAVENE PRESERVATIVE FREE	fomivirsen sodium	INJECTABLE;INJECTION	020961-001	Aug 26, 1998
Novartis	VITRAVENE PRESERVATIVE FREE	fomivirsen sodium	INJECTABLE;INJECTION	020961-001	Aug 26, 1998

Fomivirsen Sodium Market Dynamics and Financial Trajectory

Last updated: September 29, 2026

Fomivirsen sodium, marketed as Vitravene, was the first approved antisense drug and the first treatment specifically developed for cytomegalovirus retinitis in patients with AIDS. Its commercial life was short. FDA approval came in 1998, but widespread antiretroviral therapy rapidly reduced the target population and the need for intraocular CMV treatment. Novartis withdrew the product from the U.S. market in 2002, and European commercialization later ended. Fomivirsen has no meaningful current commercial revenue, active competitive market, or conventional generic-entry threat.

What is fomivirsen sodium and what was it approved to treat?

Fomivirsen sodium is a 21-nucleotide phosphorothioate antisense oligonucleotide. It binds to a messenger-RNA sequence associated with human cytomegalovirus and inhibits viral protein production.

The FDA approved Vitravene in August 1998 for the treatment of cytomegalovirus retinitis in patients with AIDS who were intolerant of, or had inadequate responses to, other approved therapies.[1] The product was administered by intravitreal injection rather than systemically.

Attribute	Fomivirsen sodium
Brand name	Vitravene
Active ingredient	Fomivirsen sodium
Drug class	Antisense oligonucleotide
Target disease	CMV retinitis
Original sponsor	Isis Pharmaceuticals, now Ionis Pharmaceuticals
Commercial partner	Novartis
FDA approval	1998
Administration	Intravitreal injection
Current status	Commercially discontinued
Current revenue base	None of commercial significance

Fomivirsen was used primarily in patients who could not tolerate intravenous ganciclovir, foscarnet, or cidofovir, or whose disease had become refractory to those therapies. The treatment was delivered by an ophthalmologist and required repeat intraocular injections.

When did fomivirsen lose commercial exclusivity and market relevance?

Fomivirsen’s market relevance declined before patent expiry became the central commercial issue. Combination antiretroviral therapy, introduced broadly in the mid-1990s, restored immune function in many patients with AIDS and sharply reduced the incidence of CMV retinitis. The addressable patient population contracted faster than the product could establish a durable specialty-market position.

Novartis discontinued Vitravene in the United States in 2002. The company cited the declining incidence of CMV retinitis associated with improved HIV treatment.[2] European commercialization also ended later as the clinical need continued to fall.

Fomivirsen commercial timeline

Year	Event	Commercial effect
1990s	Combination antiretroviral therapy expands	CMV retinitis incidence begins to decline
1998	FDA approves Vitravene	Product enters a narrow salvage-treatment market
1998-2000	Early commercial launch	Uptake constrained by injection burden and competing antivirals
2001-2002	CMV retinitis prevalence falls materially	Addressable market contracts
2002	U.S. marketing discontinued	U.S. commercial revenue ends
Later 2000s	European commercialization ends	Global commercial opportunity effectively closes
Present	No established commercial supply	No active branded market

The key loss-of-exclusivity event was therefore clinical and epidemiological rather than purely legal. A smaller patient pool, reduced treatment demand, and an invasive administration procedure weakened the product before a generic business could form.

How large was the fomivirsen market?

Fomivirsen generated only limited commercial revenue compared with major antiviral or HIV products. Public company disclosures did not establish a durable, separately reported revenue stream that would support a detailed annual sales series. Available industry accounts generally characterize Vitravene as a low-revenue product whose sales never approached the scale required to offset a shrinking CMV market.[2][3]

The market had four structural constraints:

1. The eligible population was restricted to AIDS patients with CMV retinitis.
2. Many patients could be managed by restoring immune function with antiretroviral therapy.
3. Fomivirsen required repeated intravitreal injections.
4. Existing systemic antivirals had established clinical use and broader physician familiarity.

Fomivirsen’s price could not compensate for the collapse in patient volume. Specialty products can support premium pricing when the treated population is stable or growing. Vitravene faced the opposite pattern: a high-intensity procedure in a rapidly disappearing indication.

Financial trajectory

Period	Revenue direction	Main driver
1998 launch	Low initial revenue	Narrow label and specialist administration
1999-2000	Limited penetration	Competition from existing antivirals and declining CMV incidence
2001-2002	Sharp deterioration	HAART reduces CMV retinitis cases
After 2002	U.S. revenue discontinued	Novartis exits the U.S. market
Later period	Negligible or zero commercial revenue	Product withdrawal and obsolete demand base

Neither Ionis nor Novartis developed Vitravene into a platform commercial franchise. Its importance was primarily technological and regulatory: it demonstrated that antisense oligonucleotides could receive marketing approval.

What FDA regulatory status does fomivirsen have?

Fomivirsen was FDA-approved but is no longer an actively marketed treatment in the United States. Its withdrawal was associated with commercial and epidemiological factors, not a regulatory finding that the product was unsafe or ineffective.

The original approval applied to a narrow clinical population with AIDS-related CMV retinitis. The indication did not expand into broader CMV disease, transplant medicine, congenital CMV, or systemic viral infection.

Regulatory characteristics

Fomivirsen’s regulatory profile was unusual for three reasons:

• It was an antisense oligonucleotide approved before the later wave of antisense and RNA-targeted products.
• It was administered directly into the eye.
• Its approval depended on a disease population that contracted rapidly after launch.

The product did not become a foundation for a follow-on ophthalmic franchise. Later antisense successes, including mipomersen, inotersen, nusinersen, and eteplirsen, relied on different disease models, delivery strategies, or chronic treatment markets.

What patents protected fomivirsen sodium?

Fomivirsen was protected through patents covering antisense oligonucleotide sequences, phosphorothioate chemistry, viral targets, and therapeutic use. Public sources do not support treating the patent estate as an active commercial barrier today. The product has been commercially discontinued for more than two decades, and any original U.S. exclusivity would have expired or become commercially irrelevant.

The relevant intellectual-property assets were more important during development than during the post-launch period. Antisense patent portfolios commonly included:

• Sequence-specific oligonucleotides directed to CMV transcripts.
• Chemical modifications that improve nuclease resistance.
• Pharmaceutical compositions containing the oligonucleotide.
• Methods for treating CMV infection.
• Local delivery methods, including intravitreal administration.

Patent strength

Factor	Assessment
Composition-of-matter value	Historically meaningful
Clinical-use value	Narrow because the indication was restricted
Formulation value	Limited by the small ophthalmic market
Manufacturing barrier	Moderate during the early antisense era
Current blocking value	Low
Generic litigation value	Minimal
Licensing value	Primarily historical or platform-related

No current commercial strategy would reasonably depend on asserting legacy fomivirsen patents against a generic entrant. The commercial market has already collapsed, and a prospective entrant would face demand and clinical-practice barriers rather than a strong branded-product moat.

Did fomivirsen face Paragraph IV challenges or generic competition?

There is no material record of a commercially consequential Paragraph IV campaign against Vitravene. The product’s market was too small and declining too rapidly to provide a compelling generic-launch opportunity.

A generic or follow-on entrant would face several practical obstacles:

• Low patient volume.
• Need for specialized ophthalmic administration.
• Physician and facility requirements for intravitreal injection.
• Limited incentive to conduct comparative manufacturing and stability work.
• A treatment paradigm largely displaced by antiretroviral immune restoration.

The absence of generic competition should not be interpreted as evidence of exceptionally strong patent protection. It is more accurately explained by poor market economics.

What formulation and manufacturing barriers affected fomivirsen?

Fomivirsen was supplied as an injectable oligonucleotide for intraocular administration. The formulation had to support sterility, chemical stability, dose uniformity, and safe delivery into the vitreous.

Manufacturing barriers were more significant in the late 1990s than they are today. Commercial-scale synthesis of phosphorothioate oligonucleotides required specialized chemistry, purification, analytical testing, and sterile fill-finish capabilities. These requirements could deter small competitors, but they did not create a lasting market advantage once demand disappeared.

The delivery route was a greater commercial barrier than manufacturing alone. Intravitreal dosing imposes procedure-related costs and patient burden. A product requiring repeated injections must offer a clear therapeutic advantage over systemic or locally administered alternatives. Fomivirsen’s advantage narrowed as systemic HIV control improved.

Which companies challenged or competed with fomivirsen?

No company built a major direct competing franchise around the same CMV-retinitis niche after Vitravene’s launch. Competition came primarily from established antiviral drugs and from improved HIV disease management.

Competitor or substitute	Competitive role
Ganciclovir	Established anti-CMV therapy
Foscarnet	Alternative for resistant or intolerant patients
Cidofovir	Additional systemic anti-CMV option
Combination antiretroviral therapy	Reduced the underlying CMV-retinitis population
Ophthalmic procedures and implants	Alternative local treatment approaches in selected cases

The most important competitor was not another antisense product. It was effective antiretroviral therapy.

What licensing deals supported fomivirsen?

Isis Pharmaceuticals partnered with Novartis on development and commercialization. Novartis commercialized Vitravene, while Isis contributed antisense technology and development expertise.[2][3]

The partnership illustrated the commercial model used for early antisense drugs: a biotechnology company supplied platform technology and discovery capability, while a large pharmaceutical company supplied clinical development, regulatory infrastructure, manufacturing, and commercialization. The model did not produce a durable revenue stream because the underlying disease market contracted rapidly.

There is no current licensing market of material size for fomivirsen itself. Any residual value is principally historical, including precedent for antisense development, regulatory strategy, and intellectual-property structuring.

What is the biosimilar and follow-on risk for fomivirsen?

Biosimilar risk is not relevant because fomivirsen is a chemically synthesized oligonucleotide rather than a biologic protein. A follow-on product would more likely be regulated as a generic or an oligonucleotide-specific alternative, depending on the jurisdiction and regulatory pathway.

The practical risk is low because there is no meaningful active market to capture. A new developer would need to recreate a clinical and commercial rationale for a disease that is now managed primarily through HIV control and modern anti-CMV treatment approaches.

How does fomivirsen compare with later antisense drugs?

Fomivirsen established regulatory precedent but had a weak commercial profile compared with later antisense products.

Product	Target market	Delivery	Commercial outcome
Fomivirsen	AIDS-related CMV retinitis	Intravitreal	Withdrawn after market contraction
Mipomersen	Homozygous familial hypercholesterolemia	Subcutaneous	Limited commercial adoption
Inotersen	Hereditary transthyretin amyloidosis	Subcutaneous	Specialty orphan-drug market
Nusinersen	Spinal muscular atrophy	Intrathecal	Large specialty market
Eteplirsen	Duchenne muscular dystrophy	Intravenous	Rare-disease commercial model

The comparison shows that antisense technology alone does not determine commercial value. Disease prevalence, treatment duration, reimbursement, delivery burden, clinical urgency, and competitive alternatives are decisive.

What generic launch scenarios exist for fomivirsen?

A conventional generic launch is unlikely to occur. The plausible scenarios are limited:

Scenario 1: No re-entry

This is the most likely outcome. The market remains commercially inactive because the original indication is small and alternative management is available.

Scenario 2: Academic or compassionate-use supply

A specialized manufacturer could produce limited quantities for clinical or compassionate-use needs. This would not represent a conventional branded or generic market.

Scenario 3: Reformulated local antiviral

A new product could target ocular CMV with improved dosing or delivery. Such a product would compete as a new therapeutic rather than as a straightforward Vitravene generic.

What is the current revenue exposure and investment relevance?

Current direct revenue exposure is effectively zero for the discontinued product. There is no meaningful recurring revenue stream for investors to model, no active sales trajectory, and no conventional loss-of-exclusivity event capable of causing a near-term revenue shock.

The investment relevance is historical and strategic:

• Fomivirsen validated antisense oligonucleotides as an FDA-recognized therapeutic class.
• Its commercial failure showed the risk of targeting a rapidly shrinking infectious-disease population.
• Its intravitreal delivery model highlighted the impact of administration burden on specialty-drug economics.
• Its partnership structure influenced later biotechnology-pharmaceutical collaborations.

For valuation purposes, fomivirsen should be treated as a discontinued legacy asset, not as a growth product or an active patent-protected franchise.

Key Takeaways

• Fomivirsen sodium, marketed as Vitravene, was FDA-approved in 1998 for AIDS-related CMV retinitis.
• It was the first approved antisense drug.
• Combination antiretroviral therapy rapidly reduced the CMV-retinitis population after launch.
• Novartis discontinued U.S. marketing in 2002; later European commercialization also ended.
• Public disclosures do not support a durable, separately reported revenue stream.
• There is no material current generic, biosimilar, or Paragraph IV threat.
• Legacy formulation and manufacturing patents have low present commercial value.
• The product’s principal significance is regulatory and technological, not financial.
• Current revenue exposure is negligible, and a conventional market re-entry is unlikely.

FAQs

Is fomivirsen sodium still available commercially?

No. Vitravene is not an active commercial product in the United States, and its broader commercial distribution ended after the decline of AIDS-related CMV retinitis.

What company developed fomivirsen?

Isis Pharmaceuticals, now Ionis Pharmaceuticals, developed the antisense technology, while Novartis commercialized Vitravene.

Why did Vitravene fail commercially?

Its target population declined rapidly after combination antiretroviral therapy became standard. The product also required repeated intravitreal injections and competed with established systemic antivirals.

Was fomivirsen the first antisense drug approved by the FDA?

Yes. FDA approved fomivirsen in 1998, making it the first antisense drug to receive U.S. marketing approval.

Could a company relaunch fomivirsen for CMV retinitis?

A relaunch is technically possible but commercially unlikely. The remaining patient population, existing antiviral options, delivery burden, and limited reimbursement opportunity would provide weak investment economics.

References

1. U.S. Food and Drug Administration. (1998). Vitravene (fomivirsen sodium) injection prescribing information. FDA.

2. Novartis AG. (2002). Annual report 2002. Novartis.

3. Ionis Pharmaceuticals, Inc. (Various years). Annual reports and Securities and Exchange Commission filings. Ionis Pharmaceuticals.

4. Centers for Disease Control and Prevention. (1999). Guidelines for prevention of opportunistic infections in persons infected with human immunodeficiency virus. MMWR Recommendations and Reports, 48(RR-10).

5. Crooke, S. T. (1998). Antisense research and applications. Springer.